Bristol-Myers Squibb Company (BMY) Free Cash Flow (FCF): $12.85B
The free cash flow (FCF) for Bristol-Myers Squibb Company (BMY) is $12.85B. It is below its 12-month average by 4.10% ($13.39B).
BMY Free Cash Flow (FCF) Chart
BMY Average Free Cash Flow (FCF) Chart
BMY Current vs Average Free Cash Flow (FCF) Chart
BMY Free Cash Flow (FCF) Metrics
FREE CASH FLOW (FCF)
$12.85B
FREE CASH FLOW (FCF) AVG TTM
$13.39B
FREE CASH FLOW (FCF) AVG 3Y
$12.85B
FREE CASH FLOW (FCF) AVG 5Y
$13.32B
FREE CASH FLOW (FCF) AVG 10Y
$9.16B
FREE CASH FLOW (FCF) AVG 15Y
$7.58B
FREE CASH FLOW (FCF) AVG 20Y
$6.29B
CURRENT VS TTM AVG
-4.10%
CURRENT VS 3Y AVG
-0.01%
CURRENT VS 5Y AVG
-3.56%
CURRENT VS 10Y AVG
+40.23%
CURRENT VS 15Y AVG
+69.40%
CURRENT VS 20Y AVG
+104.22%
FCF Analysis
Free Cash Flow (TTM)
$12.85B
FCF Yield
10.32%
Price/FCF
9.7
Formula: FCF = Operating Cash Flow - Capital Expenditures
Why FCF matters:
- Shows actual cash available (not accounting earnings)
- Funds dividends, buybacks, and debt reduction
- Less susceptible to accounting manipulation than net income
- Key metric for DCF valuation models
Bristol-Myers Squibb Company Free Cash Flow (FCF) Formula & Definition
Free Cash Flow represents the cash a company generates after accounting for capital expenditures. It's the cash available for dividends, buybacks, debt reduction, or reinvestment.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Bristol-Myers Squibb Company Free Cash Flow (FCF) FAQ
- What is the free cash flow (FCF) for Bristol-Myers Squibb Company (BMY)?
- The free cash flow (FCF) for BMY stock is $12.85B.
- What is the TTM average free cash flow (FCF) for Bristol-Myers Squibb Company (BMY)?
- The TTM average free cash flow (FCF) for BMY stock is $13.39B.
- What is the 3Y average free cash flow (FCF) for Bristol-Myers Squibb Company (BMY)?
- The 3Y average free cash flow (FCF) for BMY stock is $12.85B.
- What is the 5Y average free cash flow (FCF) for Bristol-Myers Squibb Company (BMY)?
- The 5Y average free cash flow (FCF) for BMY stock is $13.32B.
- What is the 10Y average free cash flow (FCF) for Bristol-Myers Squibb Company (BMY)?
- The 10Y average free cash flow (FCF) for BMY stock is $9.16B.
- What is the 15Y average free cash flow (FCF) for Bristol-Myers Squibb Company (BMY)?
- The 15Y average free cash flow (FCF) for BMY stock is $7.58B.
- What is the 20Y average free cash flow (FCF) for Bristol-Myers Squibb Company (BMY)?
- The 20Y average free cash flow (FCF) for BMY stock is $6.29B.
Bristol-Myers Squibb Company Free Cash Flow (FCF) History
| DATE | FREE CASH FLOW (FCF) |
|---|---|
| 2025-12-31 | $12.85B |
| 2024-12-31 | $13.94B |
| 2023-12-31 | $12.65B |
| 2022-12-31 | $11.95B |
| 2021-12-31 | $15.23B |
| 2020-12-31 | $13.30B |
| 2019-12-31 | $7.37B |
| 2018-12-31 | $6.12B |
| 2017-12-31 | $4.22B |
| 2016-12-31 | $1.84B |
| 2015-12-31 | $1.28B |
| 2014-12-31 | $2.62B |
| 2013-12-31 | $3.01B |
| 2012-12-31 | $6.39B |
| 2011-12-31 | $4.47B |
| 2010-12-31 | $4.07B |
| 2009-12-31 | $3.33B |
| 2008-12-31 | $2.77B |
| 2007-12-31 | $2.31B |
| 2006-12-31 | $1.29B |
| 2005-12-31 | $1.07B |
| 2004-12-31 | $2.37B |
| 2003-12-31 | $2.52B |
| 2002-12-31 | $-237.00M |
| 2001-12-31 | $4.38B |
| 2000-12-31 | $4.06B |
| 1999-12-31 | $3.52B |
| 1998-12-31 | $2.99B |
| 1997-12-31 | $1.71B |
| 1996-12-31 | $2.04B |
Related Metrics
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Christopher S. Boerner